SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype.

Hall, CL; Akhtar, MM; Sabater-Molina, M; Futema, M; Asimaki, A; Protonotarios, A; Dalageorgou, C; Pittman, AM; Suarez, MP; Aguilera, B; et al. Hall, CL; Akhtar, MM; Sabater-Molina, M; Futema, M; Asimaki, A; Protonotarios, A; Dalageorgou, C; Pittman, AM; Suarez, MP; Aguilera, B; Molina, P; Zorio, E; Hernández, JP; Pastor, F; Gimeno, JR; Syrris, P; McKenna, WJ (2020) Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype. Int J Cardiol, 307. pp. 101-108. ISSN 1874-1754 https://doi.org/10.1016/j.ijcard.2019.09.048
SGUL Authors: Asimaki, Angeliki

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB) | Preview
[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (20MB) | Preview

Abstract

BACKGROUND: Pathogenic variants in the filamin C (FLNC) gene are associated with inherited cardiomyopathies including dilated cardiomyopathy with an arrhythmogenic phenotype. We evaluated FLNC variants in arrhythmogenic cardiomyopathy (ACM) and investigated the disease mechanism at a molecular level. METHODS: 120 gene-elusive ACM patients who fulfilled diagnostic criteria for arrhythmogenic right ventricular cardiomyopathy (ARVC) were screened by whole exome sequencing. Fixed cardiac tissue from FLNC variant carriers who had died suddenly was investigated by histology and immunohistochemistry. RESULTS: Novel or rare FLNC variants, four null and five variants of unknown significance, were identified in nine ACM probands (7.5%). In FLNC null variant carriers (including family members, n = 16) Task Force diagnostic electrocardiogram repolarization/depolarization abnormalities were uncommon (19%), echocardiography was normal in 69%, while 56% had >500 ventricular ectopics/24 h or ventricular tachycardia on Holter and 67% had late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMRI). Ten gene positive individuals (63%) had abnormalities on ECG or CMRI that are not included in the current diagnostic criteria for ARVC. Immunohistochemistry showed altered key protein distribution, distinctive from that observed in ARVC, predominantly in the left ventricle. CONCLUSIONS: ACM associated with FLNC variants presents with a distinctive phenotype characterized by Holter arrhythmia and LGE on CMRI with unremarkable ECG and echocardiographic findings. Clinical presentation in asymptomatic mutation carriers at risk of sudden death may include abnormalities which are currently non-diagnostic for ARVC. At the molecular level, the pathogenic mechanism related to FLNC appears different to classic forms of ARVC caused by desmosomal mutations.

Item Type: Article
Additional Information: © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: ARVC, Arrhythmogenic cardiomyopathy, Filamin C variants, Immunohistochemistry, Late gadolinium enhancement, 1102 Cardiovascular Medicine And Haematology, Cardiovascular System & Hematology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Int J Cardiol
ISSN: 1874-1754
Language: eng
Dates:
DateEvent
15 May 2020Published
8 October 2019Published Online
18 September 2019Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
14CVD03Fondation Leducqhttp://dx.doi.org/10.13039/501100001674
PI14/01477Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PI18/0158Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PT17/0015/0043Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PI14/01676Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PI18/01231Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PT17/0015/0038Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PubMed ID: 31627847
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/111297
Publisher's version: https://doi.org/10.1016/j.ijcard.2019.09.048

Actions (login required)

Edit Item Edit Item